Katholisches Klinikum Bochum

Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline characteristics

Stephen J. Nicholls, Deepak L. Bhatt, John B. Buse et al. · American Heart Journal · 2023 · 194 citations · Full text

Guideline for the management of myasthenic syndromes

Heinz Wiendl, Angela Abicht, Andrew Chan et al. · Therapeutic Advances in Neurological Disorders · 2023 · 119 citations · Full text

The novel dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 ( <scp>GLP</scp> ‐1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective <scp>long‐acting GLP</scp> ‐1 receptor agonists

Shweta Urva, Tamer Coşkun, Corina Loghin et al. · Diabetes Obesity and Metabolism · 2020 · 116 citations · Full text

Consensus report: definition and interpretation of remission in type 2 diabetes

Matthew C. Riddle, William T. Cefalu, Philip Evans et al. · Diabetologia · 2021 · 113 citations · Full text

Metabolic Syndrome, Diabetes Management, Diabetes Epidemiology +5

Permissive hypercapnia in extremely low birthweight infants (PHELBI): a randomised controlled multicentre trial

Ulrich Thomé, Orsolya Genzel‐Boroviczény, Bettina Bohnhorst et al. · The Lancet Respiratory Medicine · 2015 · 108 citations

Neonatology, Infant Nutrition, Pediatrics +6